- Home
- FINV vs SVRA Comparison
FINV vs SVRA Comparison
Compare FINV & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FINV | SVRA |
|---|---|---|
| Founded | 2007 | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2017 | 2009 |
Fundamental Metrics
Financial Performance| Metric | FINV | SVRA |
|---|---|---|
| Price | $3.37 | $5.61 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $12.10 | $7.33 |
| AVG Volume (30 Days) | 1.1M | ★ 1.4M |
| Earning Date | 05-19-2026 | 05-13-2026 |
| Dividend Yield | ★ 6.09% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.58 | $430.87 |
| P/E Ratio | $3.87 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.22 | $3.34 |
| 52 Week High | $8.05 | $7.01 |
Technical Indicators
Market Signals| Indicator | FINV | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 29.94 | 52.77 |
| Support Level | N/A | $5.43 |
| Resistance Level | $5.17 | $6.09 |
| Average True Range (ATR) | 0.22 | 0.21 |
| MACD | -0.08 | 0.01 |
| Stochastic Oscillator | 12.72 | 73.53 |
Price Performance
Historical ComparisonAbout FINV FinVolution Group
FinVolution Group is a provider of online consumer finance in China. The company offers various loan products, making financial services available to borrowers anytime, anywhere; designs a loan transaction process, and offers tailored risk-based pricing. It offers short-term loans to borrowers to meet immediate credit needs while allowing them to gradually establish their credit history through activities on the company's platform. The company generates revenues from fees charged to borrowers. The Group's long-lived assets are located in the PRC, and its revenues are derived from within the PRC.
About SVRA Savara Inc.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).